帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Notch1 Mutation Represents a Potential Therapeutic Target to Enhance Immune Recognition in Oral Squamous Cell Carcinoma.
Notch1 Mutation Represents a Potential Therapeutic Target to Enhance Immune Recognition in Oral Squamous Cell Carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现突显了 Notch1 突变作为 OSCC 免疫识别潜在治疗靶点的可能性。
Notch1是一个抑癌基因,是头颈部鳞状细胞癌(HNSCC)中最常发生突变的基因之一。因此,研究Notch1突变对口腔鳞状细胞癌(OSCC,HNSCC的一个亚型)抗肿瘤免疫的影响具有重要临床意义。
本研究探讨了Notch1突变及免疫相关蛋白的表达。我们还利用公共数据库分析了Notch1突变对免疫微环境的影响。
我们使用qPCR检测了Notch1-4在OSCC细胞系中的表达。Notch1敲低后,分别采用CCK8和划痕愈合实验分析OSCC细胞的增殖和迁移能力。通过western blot和流式细胞术检测程序性细胞死亡配体1(PD-L1)的定位,并通过western blot评估PD-L1的表达。在47例OSCC患者的体细胞突变分析中,采用免疫组化(IHC)染色分析肿瘤浸润CD8 + T细胞与PD-L1表达之间的关系。此外,利用多种在线生物信息学工具分析癌症基因组图谱(TCGA)的数据,比较HNSCC中Notch1突变的特征。Notch1的表达因OSCC细胞系表型而异,Notch1突变与肿瘤生长显著相关,但与肿瘤浸润无关。Notch1敲低后,肿瘤细胞表面的PD-L1表达增加,而细胞质中PD-L1表达减少。在分析的47例OSCC患者中,7例(14%)存在Notch1突变。其中,5例患者(71%)表现为高肿瘤浸润CD8 + T细胞和Notch1突变。使用xCell算法进行的在线生物信息学分析显示,与Notch1野生型肿瘤相比,Notch1突变型肿瘤中初始CD8 + T细胞水平显著更高。
Notch1, a tumor suppressor gene, is one of the most frequently mutated genes in head and neck squamous cell carcinoma (HNSCC). Therefore, it is clinically important to investigate the effects of Notch1 mutations on antitumor immunity in oral squamous cell carcinoma (OSCC), a subset of HNSCC. AIMS: This study investigated Notch1 mutations and the expression of immune-related proteins. We also examined the influence of Notch1 mutations on the immune microenvironment using a public database. METHODS AND RESULTS: We examined the expression of Notch1-4 in OSCC cell lines using qPCR. After Notch1 knockdown, OSCC cell proliferation and migration were analyzed using CCK8 and wound healing assays, respectively. Localization of programmed cell death ligand 1 (PD-L1) was assessed by western blot and flow cytometry, while PD-L1 expression was evaluated by western blot. In the somatic mutation analysis of 47 OSCC patients, the relationship between tumor-infiltrating CD8 + T cells and PD-L1 expression was analyzed using immunohistochemical (IHC) staining. Furthermore, data from The Cancer Genome Atlas (TCGA) were analyzed using multiple online bioinformatics tools to compare the characteristics of Notch1 mutations in HNSCC. The expression of Notch1 varied depending on the OSCC cell line phenotype, and Notch1 mutation was significantly correlated with tumor growth but not with tumor infiltration. In Notch1 knockdown, PD-L1 expression on the tumor cell surface increased, while cytoplasmic PD-L1 expression decreased. Among the 47 OSCC patients analyzed, seven (14%) had Notch1 mutations. Of those, five patients (71%) exhibited high tumor-infiltrating CD8 + T cells and Notch1 mutation. Online bioinformatics analysis using the xCell algorithm revealed that Notch1-mutated tumors had significantly higher levels of naïve CD8 + T cells compared to Notch1 wild-type tumors.
These findings highlight Notch1 mutation as a potential therapeutic target for immune recognition in OSCC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。